Showing results 1 to 20 of 24
next >
| Issue Date | Title | Author(s) |
| 2021-03-03 | A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma | Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, S; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
| 2021-03-25 | An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability | Nagy, Z; Seneviratne, JA; Kanikevich, M; Chang, W; Mayoh, C; Venkat, P; Du, Y; Jiang, C; Salib, A; Koach, J; Carter, DR; Mittra, R; Liu, T; Parker, MW; Cheung, BB; Marshall, GM |
| 2020-10 | Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. | Tee, AE; Ciampa, OC; Wong, M; Fletcher, JI; Kamili, A; Chen, J; Ho, N; Sun, Y; Carter, DR; Cheung, BB; Marshall, GM; Liu, PY; Liu, T |
| 2021-06-01 | Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells. | Thoms, JAI; Truong, P; Subramanian, S; Knezevic, K; Harvey, G; Huang, Y; Seneviratne, JA; Carter, DR; Joshi, S; Skhinas, J; Chacon, D; Shah, A; de Jong, I; Beck, D; Gottgens, B; Larsson, J; Wong, JWH; Zanini, F; Pimanda, JE |
| 2019-11-01 | Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface | Koach, J; Holien, JK; Massudi, H; Carter, DR; Ciampa, OC; Herath, M; Lim, T; Seneviratne, JA; Milazzo, G; Murray, JE; McCarroll, JA; Liu, B; Mayoh, C; Keenan, B; Stevenson, BW; Gorman, MA; Bell, JL; Doughty, L; Hüttelmaier, S; Oberthuer, A; Fischer, M; Gifford, AJ; Liu, T; Zhang, X; Zhu, S; Gustafson, WC; Haber, M; Norris, MD; Fletcher, JI; Perini, G; Parker, MW; Cheung, BB; Marshall, GM |
| 2021-08-01 | Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. | Xiao, L; Somers, K; Murray, J; Pandher, R; Karsa, M; Ronca, E; Bongers, A; Terry, R; Ehteda, A; Gamble, LD; Issaeva, N; Leonova, KI; O'Connor, A; Mayoh, C; Venkat, P; Quek, H; Brand, J; Kusuma, FK; Pettitt, JA; Mosmann, E; Kearns, A; Eden, G; Alfred, S; Allan, S; Zhai, L; Kamili, A; Gifford, AJ; Carter, DR; Henderson, MJ; Fletcher, JI; Marshall, G; Johnstone, RW; Cesare, AJ; Ziegler, DS; Gudkov, AV; Gurova, KV; Norris, MD; Haber, M |
| 2016-06 | Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. | Carter, DR; Sutton, SK; Pajic, M; Murray, J; Sekyere, EO; Fletcher, J; Beckers, A; De Preter, K; Speleman, F; George, RE; Haber, M; Norris, MD; Cheung, BB; Marshall, GM |
| 2019-09-04 | Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis | Sutton, SK; Cheung, BB; Massudi, H; Tan, O; Koach, J; Mayoh, C; Carter, DR; Marshall, GM |
| 2019-01-01 | Increase in DNA damage by MYCN knockdown through regulating nucleosome organization and chromatin state in neuroblastoma | Hu, X; Zheng, W; Zhu, Q; Gu, L; Du, Y; Han, Z; Zhang, X; Carter, DR; Cheung, BB; Qiu, A; Jiang, C |
| 2023-04-01 | Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Seneviratne, JA; Carter, DR; Mittra, R; Gifford, A; Kim, PY; Luo, J-S; Mayoh, C; Salib, A; Rahmanto, AS; Murray, J; Cheng, NC; Nagy, Z; Wang, Q; Kleynhans, A; Tan, O; Sutton, SK; Xue, C; Chung, SA; Zhang, Y; Sun, C; Zhang, L; Haber, M; Norris, MD; Fletcher, JI; Liu, T; Dilda, PJ; Hogg, PJ; Cheung, BB; Marshall, GM |
| 2019-01-30 | Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma | Gamble, LD; Purgato, S; Murray, J; Xiao, L; Yu, DMT; Hanssen, KM; Giorgi, FM; Carter, DR; Gifford, AJ; Valli, E; Milazzo, G; Kamili, A; Mayoh, C; Liu, B; Eden, G; Sarraf, S; Allan, S; Giacomo, SD; Flemming, CL; Russell, AJ; Cheung, BB; Oberthuer, A; London, WB; Fischer, M; Trahair, TN; Fletcher, JI; Marshall, GM; Ziegler, DS; Hogarty, MD; Burns, MR; Perini, G; Norris, MD; Haber, M |
| 2018-11-15 | LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis | Dorneburg, C; Fischer, M; Barth, TFE; Mueller-Klieser, W; Hero, B; Gecht, J; Carter, DR; de Preter, K; Mayer, B; Christner, L; Speleman, F; Marshall, GM; Debatin, KM; Beltinger, C |
| 2021-09-24 | MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. | De Wyn, J; Zimmerman, MW; Weichert-Leahey, N; Nunes, C; Cheung, BB; Abraham, BJ; Beckers, A; Volders, P-J; Decaesteker, B; Carter, DR; Look, AT; De Preter, K; Van Loocke, W; Marshall, GM; Durbin, AD; Speleman, F; Durinck, K |
| 2022-08 | Mesoderm-derived PDGFRA+ cells regulate the emergence of hematopoietic stem cells in the dorsal aorta. | Chandrakanthan, V; Rorimpandey, P; Zanini, F; Chacon, D; Olivier, J; Joshi, S; Kang, YC; Knezevic, K; Huang, Y; Qiao, Q; Oliver, RA; Unnikrishnan, A; Carter, DR; Lee, B; Brownlee, C; Power, C; Brink, R; Mendez-Ferrer, S; Enikolopov, G; Walsh, W; Göttgens, B; Taoudi, S; Beck, D; Pimanda, JE |
| 2023-10-25 | Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma. | Zhai, L; Balachandran, A; Larkin, R; Seneviratne, JA; Chung, SA; Lalwani, A; Tsubota, S; Beck, D; Kadomatsu, K; Beckers, A; Durink, K; De Preter, K; Speleman, F; Haber, M; Norris, MD; Swarbrick, A; Cheung, BB; Marshall, GM; Carter, DR |
| 2024-01 | MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression. | Salib, A; Jayatilleke, N; Seneviratne, JA; Mayoh, C; De Preter, K; Speleman, F; Cheung, BB; Carter, DR; Marshall, GM |
| 2018-06-15 | Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN | Ooi, CY; Carter, DR; Liu, B; Mayoh, C; Beckers, A; Lalwani, A; Nagy, Z; De Brouwer, S; Decaesteker, B; Hung, TT; Norris, MD; Haber, M; Liu, T; De Preter, K; Speleman, F; Cheung, BB; Marshall, GM |
| 2021-07-06 | Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia | Van Thillo, Q; De Bie, J; Seneviratne, JA; Demeyer, S; Omari, S; Balachandran, A; Zhai, V; Tam, WL; Sweron, B; Geerdens, E; Gielen, O; Provost, S; Segers, H; Boeckx, N; Marshall, GM; Cheung, BB; Isobe, K; Kato, I; Takita, J; Amos, TG; Deveson, IW; McCalmont, H; Lock, RB; Oxley, EP; Garwood, MM; Dickins, RA; Uyttebroeck, A; Carter, DR; Cools, J; de Bock, CE |
